ETFs with ALXN as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|6.62%||iShares NASDAQ Biotechnology Index Fund (IBB)||+44.91 (32.87%)|
|5.06%||PowerShares Dynamic Biotech &Genome (PBE)||+1.82 (7.60%)|
|3.72%||Columbia Select Large Cap Growth ETF (RWG)||+7.33 (26.25%)|
|2.8%||PowerShares Dynamic Heathcare (PTH)||+1.74 (5.45%)|
|2.51%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+22.14 (25.27%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, and atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. ... More ...